MedPath

Evaluation of blood glucose and serum lipids lowring effects of teneligliptin in patients with type 2 diabetes mellitus

Not Applicable
Conditions
Patients with type 2 diabetes mellitus
Registration Number
JPRN-UMIN000012206
Lead Sponsor
Wakayama medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1:contrandication to teneligliptin 2:Ineligible for this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Blood pressure, LDL-c
Secondary Outcome Measures
NameTimeMethod
HbA1c, blood glucose, u-Na, s-Na, s-Cr, u-Cr, NT-proBNP, IRI, ANP, sLDL, metylglyoxal, CRP
© Copyright 2025. All Rights Reserved by MedPath